Peptide Degradation Pathways: Deamidation, Oxidation and Aggregation in Research Peptides

How research peptides degrade: deamidation, isomerization, oxidation, hydrolysis and aggregation, which residues are at risk, and how labs can detect each.

Share

A peptide that left synthesis at high purity does not stay that way on its own. Peptides change chemically and physically over time, and the rate depends on the sequence, the solvent, the temperature and how the material is handled. For a research lab, those changes show up as new peaks on a chromatogram, shifted masses, cloudy solutions or results that drift from batch to batch. This guide explains the main degradation pathways described in the pharmaceutical literature, which residues are most at risk, and how each change can be detected.

Two kinds of instability

The standard framework comes from protein pharmaceutics. Manning, Patel and Borchardt's 1989 review in Pharmaceutical Research, updated by Manning and colleagues in 2010, separates instability into two groups:

  • Chemical instability: covalent changes such as deamidation, oxidation, hydrolysis and racemization.
  • Physical instability: changes in structure or state without new covalent bonds, such as aggregation, adsorption to surfaces and precipitation.

The two are linked. The 2010 update includes a section on how chemical and physical instability interact, and oxidation is a well-documented example: a 1995 study by Li and colleagues in Biochemistry reported aggregation and precipitation of human relaxin driven by metal-catalyzed oxidation.

Deamidation and isomerization at Asn and Asp

Deamidation is the conversion of asparagine (Asn) to aspartate, and to a lesser extent glutamine to glutamate. It is one of the most studied degradation reactions in peptides because it can be fast.

Geiger and Clarke's 1987 paper in the Journal of Biological Chemistry is the classic study. Using the synthetic hexapeptide Val-Tyr-Pro-Asn-Gly-Ala, they reported:

  • A deamidation half-life of only 1.4 days at 37 °C and pH 7.4, proceeding through a cyclic succinimide intermediate.
  • The succinimide then hydrolysed (half-time 2.3 hours) and racemized (half-time 19.5 hours), giving a mixture of normal aspartyl and isoaspartyl peptides in both L and D forms.
  • Replacing Asn with Asp slowed succinimide formation about 34-fold.
  • Replacing the glycine after Asn with bulkier leucine or proline slowed degradation 33- to 50-fold, and peptide cleavage products appeared in the Asn-Leu and Asn-Pro versions.

The practical lesson is that Asn-Gly is a hot spot. The small glycine side chain lets the backbone nitrogen attack the Asn side chain easily.

Robinson and Robinson's 2001 PNAS paper, "Molecular clocks," extended this by measuring deamidation rates for 306 asparaginyl sequences in model peptides under the same physiological conditions, using a mass spectrometric method. Their data show how strongly the neighbouring residues set the rate.

How to detect it. Deamidation adds about +0.98 Da (an NH₂ group replaced by OH), which high-resolution mass spectrometry can resolve. Isoaspartate has the same mass as aspartate, so it usually needs chromatographic separation; it often appears as a nearby peak on reversed-phase HPLC.

Oxidation of Met, Cys, Trp, His and Tyr

Li, Schöneich and Borchardt's 1995 review in Biotechnology and Bioengineering names oxidation as one of the major chemical degradation pathways and lists methionine, cysteine, histidine, tryptophan and tyrosine as the most susceptible residues. They describe three main triggers:

  • contaminating oxidants, such as peroxides,
  • transition metal ions, which catalyse site-specific oxidation, and
  • light.

pH, temperature and buffer composition also influence the rate.

The review makes a point that surprises many labs: the right countermeasure depends on the mechanism. Antioxidants or radical scavengers can inhibit oxidation driven by contaminating oxidants. But for metal-catalyzed oxidation, the authors note that adding antioxidants may actually accelerate the reaction, and screening chelating agents is the more effective option.

How to detect it. Methionine sulfoxide adds +16 Da, and further oxidation to the sulfone adds +32 Da. Tryptophan oxidation products also show characteristic mass increases. Oxidized species usually elute earlier than the parent peptide on reversed-phase HPLC because they are more polar. Cysteine oxidation can also produce disulfide-linked dimers, which show up at roughly double the mass.

Hydrolysis and other backbone reactions

Peptide bonds can be cleaved non-enzymatically, especially under acidic or basic conditions. D'Hondt and colleagues' 2014 review of related impurities in peptide medicines, published in the Journal of Pharmaceutical and Biomedical Analysis, groups degradation-related impurities into several types, including:

  • Succinimide formation, as described above.
  • Diketopiperazine formation, where the first two N-terminal residues cyclize and cleave off.
  • Pyroglutamate formation, where an N-terminal glutamine or glutamate cyclizes.
  • β-elimination, which can affect residues such as cysteine and serine.

Geiger and Clarke's observation of cleavage in Asn-Leu and Asn-Pro peptides is another example of backbone breakage linked to side-chain chemistry.

How to detect it. Cleavage produces shorter fragments with lower masses, usually seen as new, earlier-eluting peaks. Pyroglutamate formation from glutamine causes a mass loss of about 17 Da (loss of ammonia).

Aggregation and adsorption

Physical instability matters even for short peptides. Hydrophobic or amphipathic sequences can self-associate into soluble oligomers or insoluble aggregates. D'Hondt and colleagues also list dimeric and oligomeric impurities among those found in peptide products.

Aggregation is affected by concentration, pH relative to the peptide's isoelectric point, ionic strength, temperature, agitation and freeze-thaw cycles. Peptides can also stick to glass and plastic surfaces, which lowers the effective concentration without any visible change.

How to detect it. Look for turbidity, a drop in recovered concentration, broadened or late-eluting HPLC peaks, or high-molecular-weight species by size-exclusion chromatography.

Why the dry state helps

The Manning 2010 update has a section on stabilization in the dried state. Removing water slows most hydrolytic and deamidation reactions, which is why research peptides are supplied lyophilized. Our peptide lyophilization guide explains the process, and the storage guide covers temperature, light and moisture control.

A sequence checklist for your lab

Before a study, scan the sequence for known risk points:

  • Asn-Gly, Asn-Ser, Asp-Gly: deamidation and isomerization risk.
  • Met, Cys, Trp: oxidation risk; limit air, light and metal contamination.
  • N-terminal Gln or Glu: pyroglutamate risk.
  • Free cysteines: dimerization risk.
  • Long hydrophobic stretches: aggregation and surface adsorption risk.

Then match the analytics to the risk. HPLC tracks new related peaks, mass spectrometry confirms what changed, and a batch certificate of analysis gives the starting point to compare against.

Frequently asked questions

What is the most common peptide degradation pathway? It depends on the sequence. Deamidation dominates in Asn-Gly-containing peptides, and oxidation dominates in peptides rich in Met, Cys or Trp.

Can HPLC purity alone catch degradation? It catches many changes as new peaks, but some products, such as isoaspartate, can co-elute or sit very close to the main peak. Pairing HPLC with mass spectrometry is more reliable. See HPLC vs mass spectrometry.

Do antioxidants always prevent oxidation? No. Li, Schöneich and Borchardt note that antioxidants can accelerate metal-catalyzed oxidation, where chelating agents are the better option.

References

  • Manning MC, Patel K, Borchardt RT. Stability of protein pharmaceuticals. Pharmaceutical Research. 1989;6(11):903-918. PMID: 2687836.
  • Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research. 2010;27(4):544-575. PMID: 20143256. doi:10.1007/s11095-009-0045-6.
  • Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. Journal of Biological Chemistry. 1987;262(2):785-794. PMID: 3805008.
  • Robinson NE, Robinson AB. Molecular clocks. Proceedings of the National Academy of Sciences USA. 2001;98(3):944-949. PMID: 11158575. doi:10.1073/pnas.98.3.944.
  • Li S, Schöneich C, Borchardt RT. Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization. Biotechnology and Bioengineering. 1995;48(5):490-500. PMID: 18623513. doi:10.1002/bit.260480511.
  • Li S, Nguyen TH, Schöneich C, Borchardt RT. Aggregation and precipitation of human relaxin induced by metal-catalyzed oxidation. Biochemistry. 1995;34(17):5762-5772. PMID: 7727437. doi:10.1021/bi00017a008.
  • D'Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis. 2014;101:2-30. PMID: 25044089. doi:10.1016/j.jpba.2014.06.012.

Research use only. All products sold by Morpheus Research are intended strictly for laboratory research and are not for human or veterinary consumption. Nothing in this article is medical advice, and no statement here is intended to diagnose, treat, cure or prevent any condition. Study findings are reported as published and should not be read as evidence of effects in people.